CDK8 and postmenopausal osteoporosis: Collectively, our findings suggest that CDK8 may be considered an attractive treatable target against various metabolic bone diseases relevant to abnormal osteoclastogenesis, including age-related osteoporosis and postmenopausal osteoporosis.